drugset / Trial / NCT02288208
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
RandomizedParallel-groupTriple-blindTreatment
Summary
This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will receive either birinapant or placebo in addition to their anti-viral therapy.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Birinapant | Small molecule | — | Intravenous |
| Background | Entecavir | Small molecule | 0.5 mg | Oral |
| Background | Tenofovir | Small molecule | 300 mg | Oral |